Kunming Sinoway Natural Pharmaceutical

Kunming Sinoway Natural Pharmaceutical, also known as Kunming Shenghuo Pharmaceutical, is a prominent Chinese pharmaceutical company specializing in natural medicine and botanical extracts. Founded in 1995 and headquartered in Kunming, Yunnan, the company focuses on the development of treatments for cardiovascular and cerebrovascular diseases using traditional Chinese medicine (TCM) principles. Its flagship product line is based on Erigeron breviscapus, specifically the Dengzhan Shengmai series, which is widely used in China for stroke recovery and heart health. In 2016, the company was acquired by China Resources Sanjiu Medical & Pharmaceutical, significantly expanding its distribution and R&D capabilities. Beyond pharmaceuticals, the company also produces health supplements and skincare products derived from natural herbal sources. It maintains large-scale GMP-certified manufacturing facilities and is a key player in the industrialization of Yunnan's botanical resources.